logo-loader

Faron Pharma makes encouraging start in Clevegen solid tumour trial

Published: 09:06 21 Feb 2019 EST

Faron Pharmaceuticals Ltd (LON:FARN) says early results from a proof of concept trial for immunotherapy cancer treatment Clevegen are encouraging. CEO Dr.Markku Jalkanen tells Proative London how there were noticeable increases in the body’s natural killer cells in the first two patients treated and no toxicity increase...something of a surprise for the team so early on in the trial. Jalkanen said: "We are very encouraged by these findings, and by the potential early clinical benefits indicated through the biochemical and tumour load indicators, following several lines of previous ineffective treatments."
Jalkanen continued, "This biomarker data will prove invaluable in helping to determine optimal doses as the trial continues and we look forward to generating further data to assess the efficacy in a larger sample of patients." The MATINS trial is a Phase I/II clinical study to investigate the safety and efficacy of Clevegen on selected metastatic/inoperable solid tumours in melanoma, hepatobiliary/hepatocellular, pancreatic, ovarian and colorectal cancers.

Faron Pharmaceuticals outlines groundbreaking work in cancer treatment -...

Dr. Markku Jalkanen, CEO of Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF), delivered a pivotal presentation on the company's groundbreaking work in cancer treatment, focusing on the reprogramming of myeloid cells to combat cancer at the Proactive One2One Investor Conference. Myeloid...

on 02/01/2024